New insights into how myasthenia gravis antibodies disrupt muscle function

Benefits in Myasthenia Gravis Extend to 52 Weeks With Inebilizumab

(MedPage Today) -- SAN DIEGO -- Inebilizumab (Uplizna) improved function and reduced disease severity for up to 52 weeks in generalized myasthenia gravis (gMG) patients who were acetylcholine receptor (AChR) antibody-positive, data from the MINT...

New insights into how myasthenia gravis antibodies disrupt muscle function

People who suffer from the autoimmune disease myasthenia gravis experience muscle weakness that can affect any of the muscles we use to blink, smile or even move our body around.

Investigational Telitacicept Significantly Improves Myasthenia Gravis Outcomes in Phase 3 Study

In a late-stage trial, telitacicept demonstrated significant and rapid clinical improvements in gMG, achieving notable symptom reductions, improved quality of life, and strong safety outcomes.

Chinese Researchers Decode Autoimmune Mechanisms of Myasthenia Gravis

Researchers reveal how autoantibodies in myasthenia gravis bind to and disrupt muscle AChRs targeting specific immune mechanisms.

Muscle Memory - The American Scholar

We take our muscles for granted: every time we step or stand—or even fall asleep!—we are experiencing a complex system of muscles moving in concert. And yet our notion of strength is still bogged down in stereotypes and preconceptions, some of them holdovers from 2,000 years In our Spring 2025 issue, Michael Joseph Gross wrote about how the ancient Greeks perceived strength—and muscles themselves—entirely differently from us. This week, Gross jo…

Myasthenia Gravis Is the Disease. FcRn Is the Target

Several drugs in development would block neonatal fragment crystallizable receptor (FcRn) as a way of reducing the autoantibodies that cause myasthenia gravis.